Focused on your Heart Health

Althera announces Roszet® approval by FDA

Althera Pharmaceuticals, a company focused on heart health, announces FDA approval of Roszet® (rosuvastatin and ezetimibe) tablets. By making this medicine available and affordable, we hope to improve long-term health of patients, including those with prior cardiovascular disease.

​

Please read the Press Release.

Please learn more about Roszet® at www.roszet.com.

​

Please read full Prescribing information at roszet.com/pi.

​

Founded in 2010, Althera develops innovative patient focused medicines to improve cardiovascular health.

​

Roszet (rosuvastatin and ezetimibe) tablets is expected to be available in pharmacies in United States in June 2021.

​

Althera’s Rosuvastatin/Ezetimibe is already approved and available to patients in more than 28 countries worldwide including all major European markets.

​

Althera’s second product Ezetimibe/Atorvastatin tablets (AL-310), is approved in both US and Europe, and is expected to be available to patients in 2021.